WGS
GeneDx Holdings Corp. (NASDAQ)
Healthcare — Diagnostics & Research
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Strong Buy
1.1 / 5
9 analysts
$72.13
+$0.42 (+0.59%)
Target:
$78.44
(8.8%)
Sign in to add WGS to a watchlist or set price alerts.
Price History
52-Week Range
Fundamentals
| Market Cap | $2.14B |
| P/E Ratio (TTM) | - |
| Forward P/E | 58.58 |
| EPS (TTM) | $-2.66 |
| Dividend Yield | - |
| Profit Margin | -17.58% |
| Revenue Growth | 17.40% |
| ROE | -30.42% |
| Debt/Equity | 66.19 |
| Recommendation | Strong Buy 1.1 |
| Analyst Target | $78.44 |
| Analysts | 9 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 67.1 |
| Beta | 1.97 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $170.87 |
| 52-Week Low | $32.21 |
| 50-Day Avg | $54.97 |
| 200-Day Avg | $96.96 |
| Avg Volume | $1.33M |
| Volume | 16.2K |
Performance Analysis
BULLISHWGS shows predominantly bullish signals based on its fundamentals and technicals.
~
Trading at 29% of its 52-week range.
+
RSI at 67.1 shows positive momentum.
~
Modest revenue growth of 17.4% year-over-year.
-
Operating at a loss with -17.6% margin.
+
Wall Street consensus is "Strong Buy" from 9 analysts.
+
Average analyst target of $78.44 implies 8.8% upside.
Recent News
Loading news...
Last updated: Jul 02, 2026 13:37 UTC
Back to Screener Export Report